tion or no clearly documented rationale; (iii) among patients with non-bleeding-related de-escalation, the rationale for switching to clopidogrel was often reasons that could have been addressed with the use of prasugrel to avoid the switch and prevent exposure to ischemic risks; and (iv) there was a numerical trend for increased myocardial infarction among patients with non-bleeding-related de-escalation.
← all excerpts
De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes.
1
—
—